United Therapeutics Corporation ($UTHR) Stock Forecast: Down 5.7% Today

What is United Therapeutics Corporation?

United Therapeutics (UTHR) is a biotechnology company focusing on developing therapies for pulmonary arterial hypertension and other diseases. The market sentiment towards UTHR has been favorable, driven by its history of impressive earnings surprises.

Why is United Therapeutics Corporation going down?

UTHR stock is down 5.7% on Apr 9, 2025 15:22

• Despite the positive market sentiment and expectations of a strong performance in the upcoming period, UTHR faced significant bearish movement today.
• This unexpected downturn may be linked to investors taking profits, potentially motivated by the anticipation of positive earnings.
• Market dynamics or external factors could have also played a role in the stock's decline, counter to the optimistic outlook for UTHR's future earnings.

UTHR Price Chart

UTHR Technical Analysis

UTHR News

Will United Therapeutics ( UTHR ) Beat Estimates Again in Its Next Earnings Report?

United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

https://www.zacks.com/stock/news/2442097/will-united-therapeutics-uthr-beat-estimates-again-in-its-next-earnings-report

Trending Today

Pepe ($PEPE) Crypto Forecast: Up 5.5% Today

Bonk ($BONK) Crypto Forecast: Up 16.6% Today

Floki ($FLOKI) Crypto Forecast: Up 5.6% Today

Sui ($SUI) Crypto Forecast: Down 7.5% Today

Worldcoin ($WLD) Crypto Forecast: Up 10.8% Today

Bittensor ($TAO) Crypto Forecast: Down 5.0% Today

Stellar ($XLM) Crypto Forecast: Up 5.3% Today

Bitcoin SV ($BSV) Crypto Forecast: Up 31.3% Today

dogwifhat ($WIF) Crypto Forecast: Up 20.9% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 5.1% Today

United Therapeutics Corporation Price History

28.07.2024 - UTHR Stock was up 5.0%

• The price target for UTHR was raised from $400 to $575, suggesting optimism and growth potential.
• The CEO selling over $2.5 million in company stock may be interpreted as profit-taking, but investors remained confident in the company's performance.
• The upbeat forecast for UTHR, along with the higher price target from analysts, probably influenced the market's bullish trend today.

28.07.2024 - UTHR Stock was up 5.3%

• The positive market sentiment surrounding UTHR's product pipeline and potential for addressing medical needs likely drove the bullish movement in the stock.
• The recent sale of over $2.5 million in UTHR stock by the company's CEO may have sparked initial investor concerns, but it was likely viewed as a strategic decision rather than a reflection of UTHR's performance.
• The overall upbeat outlook in the biotechnology industry, as seen in a recent industry comparison, may have also influenced investors and contributed to UTHR's stock's bullish movement today.

26.01.2025 - UTHR Stock was down 8.1%

• Despite United Therapeutics surpassing Q4 earnings and revenue estimates, the stock experienced a bearish movement, indicating that the market may have had higher expectations.
• Investors might have been disappointed with the company's future guidance or outlook, leading to a sell-off of the stock.
• The market may have reacted negatively to key metrics that fell short of Wall Street projections, causing a decline in UTHR's stock price.

16.09.2024 - UTHR Stock was up 2.5%

• UTHR has shown remarkable performance in the market, boasting an impressive average annual return of 33.66% over the past 5 years.
• The stock's significant bullish movement today may be attributed to its continuous growth and the favorable market sentiment towards its innovative therapies.
• Investors are showing confidence in United Therapeutics' market position and growth potential, evident in its current market capitalization of $15.89 billion.

09.03.2025 - UTHR Stock was down 5.7%

• Despite the positive market sentiment and expectations of a strong performance in the upcoming period, UTHR faced significant bearish movement today.
• This unexpected downturn may be linked to investors taking profits, potentially motivated by the anticipation of positive earnings.
• Market dynamics or external factors could have also played a role in the stock's decline, counter to the optimistic outlook for UTHR's future earnings.

12.01.2025 - UTHR Stock was up 1.2%

• The positive movement in UTHR today could stem from favorable market sentiment towards the company's recent product advancements or financial performance.
• Comparisons made between UTHR and ZTS may have played a role in boosting investor trust in UTHR, potentially positioning UTHR as an appealing investment choice.
• Investors may have viewed UTHR as a more attractive stock in terms of value compared to ZTS, leading to increased buying interest and driving up the stock price.
• In summary, today's uptick in UTHR may be a result of internal company factors as well as evaluations against industry peers in the biotechnology field.

01.02.2024 - UTHR Stock was up 5.4%

• The bullish movement in UTHR stock today could be attributed to the positive earnings call transcript for Q4 2023, indicating strong financial performance and growth prospects for the company.
• The upgraded stock rating from "buy" to "strong-buy" by analysts may have also contributed to the bullish momentum, instilling confidence in investors regarding the future outlook of United Therapeutics.
• The focus on under-the-radar biotech stocks gearing up for potential liftoff could have generated increased interest and attention towards UTHR, positioning it as a promising investment opportunity within the biotech sector.

23.01.2024 - UTHR Stock was up 3.5%

• UTHR experienced a significant bullish movement.
• The upgrade to a "Strong-Buy" rating likely boosted investor confidence.
• Q4 earnings and sales exceeded expectations, attributed to robust Tyvaso sales.
• Record Q4 revenue and growth strategy highlighted by United Therapeutics strengthened investor optimism, driving the stock price surge.

21.01.2024 - UTHR Stock was up 0.7%

• UTHR shares dropped initially on an earnings miss, but rebounded strongly due to posting record annual revenue and soaring net income in 2023.
• The bullish movement could also be attributed to UTHR's bold move of suing the FDA over a dispute with Liquidia's drug expansion, showcasing the company's determination to ensure fairness in the drug review process.
• Investors might have regained confidence in UTHR's future prospects, leading to the positive market sentiment despite the initial setback from the earnings miss.
• The upcoming earnings report scheduled for February 21, 2024, could further impact UTHR's stock performance as investors await the financial results to make informed decisions.

24.04.2024 - UTHR Stock was down 1.5%

• Downgrading UTHR from a "strong-buy" to a "buy" rating may have caused uncertainty among investors, leading to a sell-off.
• The improved relative strength of competitors like Keros Therapeutics, Ascendis Pharma ADR, Arvinas, and TG Therapeutics might have shifted investor interest away from UTHR.
• The overall positive market sentiment towards other pharmaceutical companies with upgraded RS ratings could have contributed to the bearish movement in UTHR.
• Investors may be reallocating their portfolios based on the perceived market leadership of other pharmaceutical companies, impacting UTHR's stock performance negatively.

21.01.2024 - UTHR Stock was up 2.5%

• UTHR took legal action against the FDA, alleging that the FDA allowed Liquidia Corporation to deviate from established rules in the drug approval process. This action may have boosted investor confidence, leading to the bullish market movement.
• Despite a decrease in United Therapeutics shares following an earnings miss, the company achieved record annual revenue and significantly increased net income in 2023. This strong financial performance likely contributed to the positive market sentiment.
• The legal dispute with the FDA regarding Liquidia's drug expansion and the efforts to uphold fairness in the drug review process could have attracted investor interest, potentially fueling the bullish trend in UTHR's stock.

28.02.2024 - UTHR Stock was down 5.0%

• The bearish movement in UTHR stock today could be attributed to the CEO, Martine Rothblatt, selling a substantial amount of company shares, raising concerns among investors about the company's future prospects.
• Additionally, the announcement of a $1 billion stock buyback plan by United Therapeutics may have signaled to investors a lack of better investment opportunities within the company, leading to a negative sentiment.
• The broader market trend towards value-oriented stocks might have diverted attention and investment away from UTHR, impacting its stock price negatively.
• Overall, the combination of insider selling, buyback plan, and shifting investor preferences towards bargain stocks likely contributed to the bearish movement in United Therapeutics Corp's stock today.